fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ethinyl estradiol & norethindrone

All products: general benefit

Synphasic · DIN 02187108 · 3 Phase · tablets, 21-pack

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-03-23 — choose a marketed DIN from the same-category list.Discontinued March 23, 2026 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-03-23 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-03-23 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Synphasic · DIN 02187108 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2026-03-23 · brand SYNPHASIC 21 TABLETS · ATC G03AB04 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE 0.5 MG, ETHINYL ESTRADIOL 0.035 MG, NORETHINDRONE 1.0 MG, ETHINYL ESTRADIOL 0.035 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Synphasic: Formulary list price $13.64 per unit (the source does not state the unit; exact figure $13.6400). What the ministry pays, not the patient.

Ministry pays: $13.6400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); extract: Marketed February 3, 2009; live record preferred: Cancelled Post Market March 23, 2026 (checked November 17, 2026) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02187108)

Source record
DIN 02187108: Synphasic Raw flags: sec3=Y Item: 683200059; group id 798; item number 1948; lccId None; manufacturer id PFI Source form: Tab-21 Pk; strength: 3 Phase Recorded listing: General benefit Source prices (unrounded): $13.6400; ministry $13.6400 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02187108 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); extract: Marketed February 3, 2009; live record preferred: Cancelled Post Market March 23, 2026 (checked November 17, 2026) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42889
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since March 23, 2026 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (G03A, G03AB): coverage varies; not interchangeable

  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, not a benefit
  • Ethinyl estradiol + norgestimate (Tri-Cyclen): general benefit, not a benefit
  • Drospirenone (Slynd): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + norethindrone (Minestrin 1/20): general benefit

3 more in the class list below

Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

DESOGESTREL & ETHINYL ESTRADIOL

· 12 products · General benefit · strengths: 0.15mg & 0.03mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tabs-21 Pk, Tabs-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

DROSPIRENONE & ETHINYL ESTRADIOL

· 9 products · General benefit · strengths: 3.0mg & 0.03mg, 3.0mg & 0.02mg · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & NORETHINDRONE ACETATE

· 4 products · General benefit · strengths: 0.02mg & 1mg, 0.03mg & 1.5mg · Tab-21 Pk, Tab-28 Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

MEDROXYPROGESTERONE ACETATE

· 10 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (4), Listed, not a benefit (1) · strengths: 150mg/mL, 2.5mg, 5mg, 10mg, 100mg · Inj Sol-1mL Pref Syr, Tab

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pregnancy
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. NORETHINDRONE ACETATE/ETHINYL ESTRADIOL & ETHINYL ESTRADIOL · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS LOLO® (ethinyl estradiol / norethindrone acetate and ethinyl estradiol) is indicated for: • the prevention of pregnancy. PM: https://pdf.hres.ca/dpd_pm/00077458.PDF; date DEC 12, 2013; DIN 02417456; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1. Indications BREVICON 0.5/35 and BREVICON 1/35 (norethindrone and ethinyl estradiol) are indicated for: • the prevention of pregnancy. 1.1. Pediatrics The safety and efficacy of BREVICON has been established in women of reproductive age. Use of these products before menarche is not indicated. 1.2. Geriatrics BREVICON is not indicated for use in postmenopausal women. https://pdf.hres.ca/dpd_pm/00081309.PDF PM date: 2025-08-07 Source product: BREVICON 0.5/35 TABLETS (21-DAY PACK); DIN 02187086; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.